ZKSCAN3 drives tumor metastasis via integrin β4/FAK/AKT mediated epithelial–mesenchymal transition in hepatocellular carcinoma

Jieqiong Li†, Nan Hao†, Juan Han3, Mi Zhang4, Xiaomei Li5* and Nan Yang6*

Abstract

Background: ZKSCAN3, a zinc-finger transcription factor containing KRAB and SCAN domains, has been reported to be regulated in several human cancers. However, its expression and function in hepatocellular carcinoma (HCC) remains unknown.

Methods: Expression of ZKSCAN3 in HCC was analyzed by western blotting, immunohistochemistry, and real time PCR. Its correlation with the clinicopathological characteristics and prognosis of HCC patients was analyzed. The effects of ZKSCAN3 on the migration and invasion were determined by Transwell assays. The potential downstream targets of ZKSCAN3 and related molecular mechanisms were clarified by Western blot and dual luciferase reporter assay.

Results: In this study, we demonstrated for the first time that ZKSCAN3 mRNA and protein was up-regulated in HCC tissues and cell lines. High ZKSCAN3 expression was significantly associated with poor prognostic features, including advanced TNM stage and vascular invasion. For 5-year survival, ZKSCAN3 served as a potential prognostic marker of HCC patients. Functionally, ZKSCAN3 promoted migration, invasion and EMT progress via directly binding to integrin β4 (ITGB4) promoter and enhanced its expression. Further investigation proved that ITGB4 triggers the focal adhesion kinase (FAK) to activate the AKT signaling pathway. Inactivation of FAK and AKT by their specific inhibitors respectively reversed the effects of ZKSCAN3 on HCC cells. In addition, we demonstrated that ZKSCAN3 expression was regulated by miR-124. In HCC tissues, MiR-124 has an inverse correlation with ZKSCAN3 expression.

Conclusion: We demonstrate for the first time that ZKSCAN3 is overexpressed in HCC tissues and promotes migration, invasion and EMT process through ITGB4-dependent FAK/AKT activation, which was regulated by miR-124, suggesting the potential therapeutic value for HCC.

Keywords: ZKSCAN3, Hepatocellular carcinoma, ITGB4, miR-124, EMT

Background

Hepatocellular carcinoma (HCC) is one of the most common and malignant tumors worldwide [1]. Most HCC patients are found with malignant biological characteristics due to recurrence and distant metastasis [2]. Although great improvements in diagnostic and therapeutic techniques have increased in past decades, the
outcome is still unsatisfactory due to recurrence and distant metastasis [3]. Therefore, clarifying the biological and molecular mechanisms of HCC metastasis and exploring the possible treatments are urgently required.

ZKSCAN3 (ZNF306) is a family member of the KRAB and SCAN domain-containing zinc-finger transcription factors [4]. ZKSCAN3 has been reported to be a novel transcription factor that upregulates gene-coding proteins involved in cellular functions such as apoptosis, proliferation, migration, invasion and autophagy [5, 6]. For instance, ZKSCAN3 promotes bladder cancer cell proliferation, migration and invasion [7]. ZKSCAN3 was overexpressed in cervical cancers and correlated with a poor clinical outcome [8]. Moreover, ZKSCAN3 facilitates liver metastasis of colorectal cancer associated with CEA-expressing tumor [9]. ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion [10]. Collectively, these results suggest that ZKSCAN3 modulates the expression of genes favoring cancer progression. However, molecular mechanisms underlying the function of ZKSCAN3 in HCC progression remained poorly understood.

Tumor metastasis is a dynamic, multistep and multifactorial process [11]. Epithelial to mesenchymal transition (EMT) is the process by which cells lose their epithelial phenotype and acquire the characteristics of mesenchymal cells [12]. EMT is an important biological process and contributes to metastasis through invasion of epithelial-derived malignant cells [13]. During EMT process, cells lose the adhesive properties and undergo alternations in polarity and reorganization of the cytoskeleton in association with the upregulation of extracellular matrix components and the acquisition of migratory and invasive properties [14]. Therefore, inhibition of EMT progress has attracted great interest in HCC metastasis therapy.

Here, we demonstrated that ZKSCAN3 was up-regulated in HCC and its overexpression was associated with malignant prognostic features and reduced survival of HCC patients. ZKSCAN3 promoted the metastasis of HCC cells in vitro and in vivo. Furthermore, we confirmed that ZKSCAN3 promoted FAK/AKT signaling pathway through directly binding to the integrin β4 promoter. miR-124 regulated ZKSCAN3 expression in HCC cells. Therefore, our data confirm that ZKSCAN3 plays a critical role in HCC progression and represent a potential target for HCC diagnosis and treatment.

Materials and methods

Clinical specimens and cell culture

HCC tissues and adjacent non-tumor tissues were obtained from patients who received surgical resection at the First Affiliated Hospital of Xi’an Jiaotong University. No patients received preoperative chemo- or radiotherapy before surgery. All the specimens were snap-frozen in liquid nitrogen and kept at − 80 °C after surgical removal. This study was approved by the Ethics Committee of this hospital. The written informed consents had been obtained from all patients before study. The HCC cell lines (Hep3B, Huh7, SMMC-7721, MHCC-97H and HCCLM3) and normal hepatic cell line (LO2) were commercially obtained from the Institute of Biochemistry and Cell Biology (Chinese Academy of Sciences, Shanghai, China). Cell culture was performed in DMEM medium (Thermo Fisher, Grand Island, NY, USA) which containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA) and 100 U/ml penicillin–streptomycin mixture (Beyotime Institute of Biotechnology, Haimen, China). The conditions for cell culture are as follows: a humidified atmosphere with 5% CO₂ at 37 °C.

RNA extraction and quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from tissues or cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. Quantitative real-time PCR was performed using SYBR Premix Ex Taq II (Takara). TaqMan microRNA assays (Applied Biosystems, Foster City, California, USA) were used to quantify the expression levels. The amount of each target gene was quantitated by the comparative C (T) method using GAPDH as the normalization control. qPCR primers: GAPDH (HQP064347), ZKSCAN3 (HQP058846) and miR-124 (HmiRQP0073) were purchased from GeneCopoeia (Guangzhou, China).

Western blot

Immunohistochemical analysis status was performed as our previously publication [15]. Cell lysates were prepared using RIPA lysis Buffer (RIPA; Pierce, Rockford, IL). Then protease inhibitors were added into lysates. A bicinechonic acid (BCA) kit (Beyotime Institute of Biotechnology, Shanghai, China) was used to determine protein concentration. Subsequently, protein was separated in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) membrane and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Merck KGaA, Germany). Tris-buffered saline (TBS) containing 5% nonfat milk was used to block the membranes for an hour at room temperature. Thereafter, the membranes were incubated with specific primary antibodies (ZKSCAN3, Abcam ab223477) at 4 °C overnight. Subsequently, HRP-conjugated secondary antibody goat anti-rabbit IgG (1:2000, Abcam) was added and incubated for 2 h at room temperate. GAPDH was considered as the internal control. Bands signal were...
detected using the enhanced chemiluminescence (ECL; Millipore, Merck KGaA, Germany).

**Ethynyl deoxyuridine (EdU) incorporation assay**
EdU incorporation assay was performed with the EdU kit (Roche, Indianapolis, IN, USA) in accordance with the manufacturer’s instruction. Results were acquired using the Zeiss fluorescence photomicroscope (Carl Zeiss, Oberkochen, Germany) and quantified via counting at least five random fields.

**Luciferase reporter assay**
The 3′-UTR of ZKSCAN3 containing predicted miR-124 binding sites (both wild type and mutant) were subcloned into the pmirGLO vector (Promega, Madison, WI, USA). For the luciferase reporter assay, HCC cells were transfected with different combinations of miR-124 mimics, control mimics and pGL3-ZKSCAN3 3′-UTR wild type or mutant. The relative luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) and normalized to Renilla activity.

**Chromatin immunoprecipitation assay**
Chromatin immunoprecipitation assay was performed using a commercial kit (Upstate Biotechnology) according to the manufacturer’s instructions. The PCR primers are for ITGB4 (specific 5′, 5′-GGGAGAGACAGCAGGAGGGAC-3′; specific 3′, 5′-CTCTGGGCACACCTGCTCCT-3′; nonspecific 5′, 5′-ATGGCAGGAACAGGGCA-3′; nonspecific 3′, 5′-GCCATCCTCTTCTCTCTGAG-3′).

**Transwell assay**
The capacity of cells migration and invasion was evaluated via transwell assay. The upper chamber was pre-coated with BioCoat Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) for invasion assay, whereas migration assay was not pre-coated with BioCoat Matrigel. Subsequently, 200 μl cells were seeded into upper chamber which mixed with serum-free medium, 500 μl DMEM medium containing 10% FBS was added into the lower chamber. After 24 h incubation, cells on the upper chamber surface were removed using cotton swabs. Cells on the lower surface were fixed in 4% paraformaldehyde and stained with 0.5% crystal violet. Finally, NIS Elements image software (Nikon, Tokyo, Japan) was used to detect the number of migrating and invading cells.

**Immunohistochemistry (IHC) staining and scoring**
Immunohistochemical analysis status was performed as our previously publication [16].

In vivo metastasis assay
4–6-week-old male BALB/c nude mice (Centre of Laboratory Animals, The Medical College of Xi’an Jiaotong University, Xi’an, China) were randomized into two groups (n=5). Transfected cells (1 × 10⁶) were injected into the tail veins for the establishment of the pulmonary metastatic model. Mice were sacrificed 3 weeks post-injection and examined microscopically by H&E staining for the development of lung metastatic foci. Animals were housed in cages under standard conditions. All in vivo protocols were approved by the Institutional Animal Care and Use Committee of Xi’an Jiaotong University.

**Statistical analysis**
Statistical analyses were performed with SPSS 17.0 software (Abbott Laboratories, Chicago, IL). Data represent mean±standard deviation (SD) of more than two independent experiments. A two-sided Student’s t-test and one-way ANOVA were separately used to compare the statistical differences. The Kaplan–Meier method was used to estimate the overall survival (OS) of HCC patients with high or low level of ZKSCAN3. Expression association of genes in HCC tissues was analyzed with Pearson’s correlation analysis. Difference was considered statistically significant when P < 0.05.

**Results**

**ZKSCAN3 is up-regulated in HCC and correlates with patients’ survival**
To explore the role of ZKSCAN3 in HCC, the expression of ZKSCAN3 mRNA and protein was determined by qRT-PCR and western blot. The results showed that the ZKSCAN3 mRNA and protein was significantly higher than that in adjacent non-tumor tissues (P < 0.05, Fig. 1a, b). Furthermore, we performed IHC staining to confirm ZKSCAN3 expression and found the IHC scores of ZKSCAN3 in HCC tissues was obviously increased compared to normal tissues (P < 0.05, Fig. 1c). Furthermore, our results showed that ZKSCAN3 was increased in HCC cells compared with normal hepatic cells LO2 (P < 0.05, Fig. 1d). High ZKSCAN3 expression was found in those with high aggressive behavior cells MHCC-97H and HCCLM3. Therefore, we proposed that ZKSCAN3 plays a role as a tumor promoter in HCC progression.

**Overexpressed ZKSCAN3 is associated with malignant clinic-pathological characteristics**
To illustrate the clinical role of ZKSCAN3, we analyzed the relevance between ZKSCAN3 and the clinicopathological features and prognosis of HCC patients. We determine the mean value as the cut-off and high
ZKSCAN3 was significantly associated with vascular invasion and advanced TNM stage ($P=0.007$, 0.013, respectively, Table 1). More intriguingly, Kaplan–Meier survival analysis cure showed that increased ZKSCAN3 in HCC patients had a shorter overall survival (OS) and disease-free survival (DFS) in HCC patients ($P=0.0032$, 0.0049, respectively, Fig. 1e). To further determine the relationship between ZKSCAN3 and the prognosis of other cohort HCC patients, 182 patients with ZKSCAN3 high expression and 182 patients with ZKSCAN3 low expression were analyzed in GEPIA ($P<0.05$, Fig. 1f). These results manifested that ZKSCAN3 had significant pathological implications in HCC development.

ZKSCAN3 promoted HCC cell migration and invasion in vitro and in vivo
To scrutinize how ZKSCAN3 promotes the progression of HCC in vitro, we transfected Hep3B with ZKSCAN3 overexpression vectors and HCCLM3 with lentivirus containing inhibitory ZKSCAN3 shRNA to perform gain- and loss-of-function experiments, respectively ($P<0.05$, Fig. 2a, c). Transwell assays showed that ZKSCAN3 overexpression significantly promoted the migration and invasion of Hep3B cells ($P<0.05$, Fig. 2b), while ZKSCAN3 knockdown remarkably inhibited migration and invasion of HCCLM3 cells ($P<0.05$, Fig. 2d). ZKSCAN3 also regulated cell proliferation of HCC cells ($P<0.05$, Additional file 1: Fig.
Moreover, to investigate the effects of ZKSCAN3 on cell metastasis in vivo, we used tail vain injection to construct lung metastasis model. The data showed that ZKSCAN3 overexpression significantly increased the number of lung metastasis of Hep3B cells whereas ZKSCAN3 knockdown reduce lung metastasis amounts (P < 0.05, Fig. 2e). These results suggest that ZKSCAN3 plays an important role in HCC aggressiveness.

**ZKSCAN3 promotes EMT process in HCC**

To evaluate the functional role of ZKSCAN3 on EMT, we performed western blot and found that ZKSCAN3 overexpression decreased epithelial marker E-cadherin, while increased mesenchymal markers N-cadherin and Vimentin (P < 0.05, Fig. 3a). Conversely, ZKSCAN3 knockdown showed the opposite effects (P < 0.05, Fig. 3b). Moreover, IF showed the similar effects of ZKSCAN3 on EMT progress (Fig. 3c). Finally, we demonstrated that E-cadherin was lower in high ZKSCAN3 expression HCC tissues while N-cadherin and Vimentin was remarkably higher in high ZKSCAN3 expression HCC tissues than that in low ZKSCAN3 HCC tissues (P < 0.05, Fig. 3d). Taken together, our data suggest that ZKSCAN3 was an activator of EMT process in HCC.

**ZKSCAN3 induces integrin β4 expression via directly binding to its promoter**

To investigate the underlying mechanism and because the predicted structure features (tandem zinc fingers) are often present in transcription factors, the sequence analysis of the integrin β4 (ITGB4, also known as CD104) promoter conform to the consensus KRDGGGG sequence. To confirm this, we first examined the impact of ZKSCAN3 expression on ITGB4. We found that ZKSCAN3 overexpression promoted ITGB4 mRNA and protein expression while ZKSCAN3 knockdown reduced

| Clinical parameters       | Cases (n) | Expression level | P value (*P < 0.05) |
|---------------------------|-----------|------------------|---------------------|
| Age (years)               |           | ZKSCAN3\^\text{High} (n = 51) | ZKSCAN3\^\text{Low} (n = 50) |
| < 60 years                | 65        | 35               | 30                  | 0.365 |
| ≥ 60 years                | 36        | 16               | 20                  | 0.494 |
| Gender                    |           |                  |                     |
| Male                      | 80        | 39               | 41                  | 0.140 |
| Female                    | 21        | 12               | 9                   | 0.199 |
| Tumor size (cm)           |           |                  |                     |
| < 5 cm                    | 72        | 33               | 39                  |        |
| ≥ 5 cm                    | 29        | 18               | 11                  |        |
| Tumor number              |           |                  |                     |
| Solitary                  | 84        | 40               | 44                  |        |
| Multiple                   | 17        | 11               | 6                   |        |
| Edmondson                 |           |                  |                     |
| I + II                    | 23        | 9                | 14                  | 0.215 |
| III + IV                  | 78        | 42               | 36                  |        |
| TNM stage                 |           |                  |                     |
| I + II                    | 76        | 33               | 43                  | 0.013* |
| III + IV                  | 25        | 18               | 7                   |        |
| Vascular infiltration     |           |                  |                     |
| Present                   | 16        | 13               | 3                   | 0.007* |
| Absent                    | 85        | 38               | 47                  |        |
| AFP                       |           |                  |                     |
| < 400 ng/ml               | 24        | 11               | 13                  | 0.601 |
| ≥ 400 ng/ml               | 77        | 40               | 37                  |        |
| HBsAg                     |           |                  |                     |
| Positive                  | 91        | 45               | 46                  | 0.527 |
| Negative                  | 10        | 6                | 4                   |        |

HCC hepatocellular carcinoma, AFP alpha-fetoprotein, TNM tumor-node-metastasis

* Statistically significant
Fig. 2  ZKSCAN3 promotes HCC cell migration and invasion in vitro and in vivo.  

a  Hep3B cells that were transfected with corresponding ZKSCAN3 overexpression vectors were subjected to WB for ZKSCAN3.  
b  Cell migration and invasion as measured by Transwell assays were promoted by overexpression of ZKSCAN3 in Hep3B cells.  
c  HCCLM3 cells that were transfected with ZKSCAN3 shRNA and negative control were subjected to WB for ZKSCAN3.  
d  Cell migration and invasion as measured by Transwell assays were inhibited by knockdown of ZKSCAN3 in HCCLM3 cells.  
e  Representative HE staining of lung metastasis of Hep3B or HCCLM3 transfected with respective ZKSCAN3 vector (×100). EV, empty vectors.  
n = three independent experiments.  *P < 0.05
ITGB4 mRNA and protein expression (P < 0.05, Fig. 4a, b). To better understand the correlation between ZKSCAN3 and ITGB4 in HCC tissues, immunohistochemical staining was performed. ZKSCAN3 protein levels in HCC tissues positively correlated with ITGB4 expression (R = 0.6802, P < 0.001, Fig. 4c). Moreover, the data from GEPIA showed that ZKSCAN3 expression has a positive correlation with ITGB4 expression (P < 0.05, Fig. 4d), which also confirmed the correlation between ZKSCAN3 and ITGB4. To investigate whether ZKSCAN3 directly
binds to ITGB4 promoter, ChIP assay was performed in HCCLM3 cells. In chromatin fractions pulled down by anti-ZKSCAN3 antibody, ITGB4 promoter was detected (Fig. 4e). To determine whether the binding of ZKSCAN3 activates ITGB4 promoter, we constructed a full-length ITGB4 luciferase promoter vector and co-transfected this reporter construct with or without ZKSCAN3 cDNA into Hep3B cells. Luciferase analysis showed that ZKSCAN3 overexpression significantly increased ITGB4 promoter activity in Hep3B cells (P < 0.05, Fig. 4f) while the promoter mutant almost abolished the transactivation of ITGB4 promoter by ZKSCAN3. To explore the role of ITGB4 in ZKSCAN3 mediated migration, invasion and EMT, we knockdown ITGB4 in ZKSCAN3-overexpressing cells. Transwell assay for migration and invasion (g) and western blot (h) for EMT markers were performed. *P < 0.05
overexpression Hep3B cells. ITGB4 knockdown at least partially rescued the promotion of ZKSCAN3 overexpression in HCC migration and invasion (P < 0.05, Fig. 4g) and EMT progress (P < 0.05, Fig. 4h), suggesting that ITGB4 was involved in ZKSCAN3-mediated migration and EMT process.

**AKT phosphorylation acts downstream of ZKSCAN3 to promote migration and invasion of HCC cells**

AKT phosphorylation signaling has been shown to promote multiple aspects of tumor development including migration and invasion [17]. We demonstrated that ZKSCAN3 overexpression promoted AKT phosphorylation while ZKSCAN3 knockdown reduced the AKT phosphorylation (P < 0.05, Fig. 5a). Moreover, ITGB4 knockdown also inhibited AKT phosphorylation in HCCLM3 cells (P < 0.05, Fig. 5b). We inquired whether AKT phosphorylation is necessary for migration and invasion of HCC by using the AKT inhibitor MK2206. We found that ZKSCAN3 induced migration, invasion and EMT of HCC cells was significantly reversed by the addition of MK2206 (P < 0.05, Fig. 5c, d). We conclude from these data that AKT signaling is necessary for ZKSCAN3-induced migration and invasion of HCC cells.

**ITGB4 activates AKT phosphorylation by FAK rather than SRC**

Integrins, without intrinsic tyrosine kinase activity, signal through the recruitment and activation of non-receptor tyrosine kinases, such as FAK and SRC [18, 19]. We demonstrated that ITGB4 overexpression promoted FAK and SRC phosphorylation while ITGB4 knockdown showed opposite effects (P < 0.05, Fig. 6a). To investigate who mediated the AKT phosphorylation, the next diagram shows the results.
experiment was performed in the presence of FAK inhibitor PF573228 or SRC inhibitor Dasatinib. As shown in Fig. 6b, the addition of PF573228 suppressed the activation of AKT, while the inhibitor of SRC (Dasatinib) could not. Finally, we found that the FAK inhibitor PF573228 significantly inhibited the migration, invasion and EMT of HCC cells (P < 0.05, Fig. 6c, d). Taken together, these findings suggest that the ZKSCAN3-ITGB4 activate the FAK/AKT signaling pathway to confer the migration, invasion and EMT of HCC.

ZKSCAN3 expression is regulated by miR-124

Previous studies reported that dysregulated miRNAs were involved in HCC progression [20, 21]. To clarify the upstream that ZKSCAN3 was up-regulated, we searched the database Targetscan to predict that miR-124 could bind to the 3'UTR of ZKSCAN3 (Fig. 7a). We performed luciferase reporter assays to show that miR-124 overexpression significantly inhibited whereas miR-124 knockdown promoted the luciferase activity of HCC cells with wild-type ZKSCAN3 3'UTR (P < 0.05, Fig. 7b). However, the activity in mild-type ZKSCAN3 3'UTR had no change (Fig. 7b). Moreover, miR-124 overexpression significantly inhibited while miR-124 knockdown promoted ZKSCAN3 mRNA and protein in HCC cells (P < 0.05, Fig. 7c, d). In HCC tissues, our results showed that miR-124 was down-regulated in HCC tissues compared to adjacent non-tumor tissues (P < 0.05, Fig. 7e), which was consistent with previous studies. We also confirmed an inverse correlation between ZKSCAN3 mRNA and miR-124 in HCC tissues (r = −0.6916, P < 0.05, Fig. 7f). Collectively, we demonstrated that miR-124 regulated ZKSCAN3 expression in HCC tissues.

Discussion

ZKSCAN3 (ZNF306) is a member of the KRAB and SCAN domain-containing zing-finger transcription factor family and a potential candidate oncogene and therapeutic target [22]. Yang et al. reported that ZKSCAN3...
was overexpressed in colorectal tumor tissue due to gene amplification [23]. Moreover, ZKSCAN3 was increased in gastric carcinoma and was an independent prognostic parameter for overall survival [24]. Moreover, ZKSCAN3 induction represents a mechanism by which myeloma cells can induce Cyclin D2 dysregulation and contribute to disease pathogenesis [25]. In the present study, we confirmed that ZKSCAN3 was up-regulated in HCC compared with adjacent non-tumor tissues. Clinical data showed that high ZKSCAN3 was significantly correlated with advanced TNM stage and vascular invasion of HCC patients. In addition, we demonstrated that ZKSCAN3 expression correlated with the metastatic potential of HCC cell lines, with the highest expression level in HCCLM3 cells, which have the high metastatic potential. Moreover, ZKSCAN3 was found to be an important prognostic marker for 5-year OS and DFS in HCC patients. These results indicated that ZKSCAN3 play a critical role in aggressive and metastasis in HCC and maybe a biomarker of unfavorable prognosis.

In order to investigate the biological function of ZKSCAN3 in HCC, we performed gain- and loss-of-function experiment to confirm that ZKSCAN3 promoted migration and invasion of HCC cells by regulating EMT phenotype progression. We used western blot analysis and immunofluorescence to confirm that ZKSCAN3 regulates the EMT process. EMT is an important biological process and contributes to metastasis through invasion of epithelial-derived malignant cells. To investigate how ZKSCAN3 regulated EMT in HCC, our data invoke integrin β4 (ITGB4) as a direct target and downstream effector of ZKSCAN3. Its expression is up-regulated in HCC supposedly due in part to ZKSCAN3 as we have shown herein. ITGB4 has recently emerged as a mediator of cancer development and tumor progression in HCC [26, 27]. ITGB4 promotes cell invasion and EMT through the modulation of Slug expression in HCC [28]. Further molecular studies demonstrate that AKT was activated by ZKSCAN3/ITGB4 and mediated the cell migration, invasion and EMT of HCC cells. Many kinases act downstream of integrins to promote metastasis of HCC, including FAK and SRC [26]. Our results show that ZKSCAN3/ITGB4 triggered FAK rather than SRC to activate the AKT signaling. Inactivation of FAK and AKT by their specific inhibitors respectively both inhibited the migration, invasion and EMT of HCC cells. Previous studies reported there are many signal pathways regulated by integrins to promote tumor progression, such as ERK/MAPK and NF-κB [29]. Therefore, we conclude that ZKSCAN3 bound to ITGB4 promoter to increase its transcription and expression and activate the FAK/AKT pathway in HCC to promote the migration, invasion and EMT of HCC cells.

Previous studies showed that ZKSCAN3 was overexpressed due in part to gene amplification in colorectal cancers and multiple myeloma [23, 25]. Here, we searched database and showed that miR-124 could bind with ZKSCAN3 3’UTR. Luciferase assays showed that miR-124 directly bind to the 3’UTR of ZKSCAN3. In addition, miR-124 negatively regulated the expression of ZKSCAN3 mRNA and protein in HCC cells. Previous studies reported that miR-124 suppressed growth of human HCC by targeting STAT3 [30]. MiR-124 inhibited the migration and invasion of HCC cells by suppressing...
integrin αv expression [31]. MiR-124 inhibited progression of HCC by targeting KLF4 and promises a novel diagnostic marker [32]. These data further confirm that miR-124 exerts a tumor suppressor in HCC [33]. In conclusion, these data suggest that ZKSCAN3 was a downstream target of miR-124 in HCC.

Conclusion
We reported for the first time that ZKSCAN3 was upregulated in HCC tissues and cells. Its overexpression was associated with malignant clinical features and unfavorable prognosis. We proved that ZKSCAN3 promotes migration, invasion and EMT progress by directly binding to ITGB4 promoter and trigger the FAK-AKT pathway. Moreover, miR-124 regulated ZKSCAN3 expression in HCC cells. These data indicated that ZKSCAN3 was an important biomarker of HCC progression and a novel and attractive therapeutic target for HCC treatment.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01307-7.

Additional file 1: Fig. S1. Edu staining to show that ZKSCAN3 overexpression significantly promoted cell proliferation in Hep3B cells while ZKSCAN3 knockdown inhibited the proliferation of HCCLM3 cells.

Abbreviations
ITGB4: Involve integrin β4; HCC: Hepatocellular carcinoma; RT-qPCR: Real-time reverse transcription polymerase chain reaction; SD: Standard deviation; OS: Overall survival; EMT: Epithelial to mesenchymal transition.

Acknowledgements
This study was supported by research members for their substantial experiment results.

Authors’ contributions
Conception and design: NY, XL. Development of methodology: JL, XL, NY. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): JL, NH, JH, MZ. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): NY, JL, XL. Administrative, technical, or material support (i.e., reporting or organizing data): JL, NH, JH, MZ. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81773123, 81874069). The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated during this study are included in this article.

Ethics approval and consent to participate
Written consents were obtained from all subjects. This study was approved by the Research Ethics Committee of Xi’an Jiaotong University and the first affiliated hospital with Xi’an Jiaotong University. Written informed consent was obtained from all subjects.

Consent for publication
Informed consent was obtained from all individual participants included in the study.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Nurse, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. 2 Department of Surgical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. 3 Department of Intensive Care Unit, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. 4 Department of Nurse, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China. 5 School of Nurse, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. 6 Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an 710061, Shaanxi, China.

Received: 11 March 2020 Accepted: 28 May 2020
Published online: 05 June 2020

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
3. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.
4. Urutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol. 2003;4(10):231.
5. Chauhan S, Goodwin JJ, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell. 2013;50(1):16–28.
6. Li Y, Xu M, Ding X, Yan C, Song Z, Chen L, Huang X, Wang X, Jian Y, Tang G, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol. 2016;18(10):1065–77.
7. Kawahara T, Inoue S, Ide H, Kashihara E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, et al. ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. Oncotarget. 2016;7(33):53599–610.
8. Lee S, Cho YE, Kim JY, Park JH. ZKSCAN3 upregulation and its poor clinical outcome in uterine cervical cancer. Int J Mol Sci. 2018;19(10):2859–69.
9. Kim CW, Roh SA, Tak KH, Koh BW, Ha YJ, Cho DH, Kim SY, Kim YS, Kim JC. ZKSCAN3 facilitates liver metastasis of colorectal cancer associated with CEA-expressing tumor. Anticancer Res. 2016;36(5):2397–406.
10. Chi Y, Xu H, Wang F, Chen X, Shan Z, Sun Y, Fan Q. ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion. Biochem Biophys Res Commun. 2018;503(4):2583–9.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou Y, Brooks M, Reinhard F, Zhang CC, Shippstins M, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
12. Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Investig. 2009;119(6):1420–8.
13. Yao B, Li Y, Wang L, Chen T, Ni Y, Liu Q, Liu Z. MicroRNA-3194-3p inhibits metastasis and epithelial–mesenchymal transition of hepatocellular carcinoma by decreasing Wnt/beta-catenin signaling through targeting BCL9. Arsf Cells Nanomed Biotechnol. 2019;47(1):3885–95.
14. Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, Constantin C, Neagu M. The role of matrix metalloproteinases in the epithelial–mesenchymal transition of hepatocellular carcinoma. Anai Cell Pathol. 2019;2019:9423907.
15. Yang N, Chen J, Zhang H, Wang X, Yao H, Peng Y, Zhang W. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KL110 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8(8):e2975.
16. Liu Z, Wang Y, Dou C, Xu M, Sun L, Wang L, Yao B, Li Q, Yang W, Tu K, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics. 2018;8(17):4649–63.
17. Dou C, Zhou Z, Xu Q, Liu Z, Zeng Y, Wang Y, Li Q, Wang L, Yang W, Liu Q, et al. Hypoxia-induced TUF1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca(2+)/PI3K/AKT pathway. Oncogene. 2019;38(8):1239–55.
18. Kumar CC. Signaling by integrin receptors. Oncogene. 1998;17(11):1365–73.
19. Soung YH, Gil HJ, Clifford JL, Chung J. Role of alphabeta4 integrin in cell motility, invasion and metastasis of mammary tumors. Curr Protein Pept Sci. 2011;12(1):23–9.
20. Liu Z, Wang Y, Dou C, Sun L, Li Q, Wang L, Xu Q, Wang W, Liu Q, Tu K. MicroRNA-146b promotes tumor progression by activating PAR-gamma-mediated AKT signaling in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):49.
21. Sun L, Wang L, Chen T, Yao B, Wang Y, Li Q, Yang W, Liu Z. microRNA-1914, which is regulated by IncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC. J Cell Mol Med. 2019;23(12):8292–304.
22. Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiayang Y, Gao L, An G, Yang N, et al. The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol. 2012;44(7):1166–73.
23. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008;68(11):4321–30.
24. Takano Y, Shida A, Fujisaki M, Mitsumori N, Yanaga K. Prognostic significance of ZKSCAN3 (ZNF306) expression in gastric carcinoma. Anticancer Res. 2020;40(1):81–6.
25. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JI, et al. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011;30(11):1329–40.
26. Leng C, Zhang ZG, Chen WX, Luo HP, Song J, Dong W, Zhu XR, Chen XP, Liang HF, Zhang BX. An integrin beta4-EGFR unit promotes hepatocarcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. Cancer Lett. 2016;376(1):188–96.
27. Yang L, Zhang L, Wu Q, Boyd DD. Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem. 2008;283(50):35295–304.
28. Li XL, Liu L, Li DD, He YP, Guo LH, Sun LP, Liu LN, Xu HX, Zhang XP. Integrin beta4 promotes cell invasion and epithelial–mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Sci Rep. 2017;7:40646.
29. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5(10):816–26.
30. Lu Y, Yue X, Cui Y, Zhang J, Wang K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 2013;441(4):873–9.
31. Cai QQ, Dong YW, Wang R, Qi B, Guo JX, Pan J, Liu YY, Zhang CY, Wu XZ. MiR-124 inhibits the migration and invasion of human hepatocellular carcinoma cells by suppressing integrin alphaV expression. Sci Rep. 2017;7:40733.
32. Wu LP, Wu J, Shang A, Yang M, Li LL, Yu J, Xu LR, Wang CB, Wang WW, Zhu JJ, et al. miR-124 inhibits progression of hepatocarcinoma by targeting KLF4 and promises a novel diagnostic marker. Artif Cells Nanomed Biotechnol. 2018;46(sup1):159–67.
33. Lang Q, Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 2012;426(2):247–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.